Enzo Biochem, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ENZB research report →
Companywww.enzo.com
Enzo Biochem, Inc. , an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics.
- CEO
- Kara Cannon
- IPO
- 1980
- Employees
- 125
- HQ
- New York City, NY, US
Price Chart
Valuation
- Market Cap
- $36.59M
- P/E
- -8.47
- P/S
- 2.66
- P/B
- 0.84
- EV/EBITDA
- -0.67
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 45.64%
- Op Margin
- -36.34%
- Net Margin
- -31.49%
- ROE
- -9.61%
- ROIC
- -10.52%
Growth & Income
- Revenue
- $31.91M · 2.72%
- Net Income
- $-26,078,000 · -228.54%
- EPS
- $-0.51 · 59.84%
- Op Income
- $-9,817,000
- FCF YoY
- 32.54%
Performance & Tape
- 52W High
- $1.19
- 52W Low
- $0.25
- 50D MA
- $0.66
- 200D MA
- $0.63
- Beta
- 1.17
- Avg Volume
- 382.19K
Get TickerSpark's AI analysis on ENZB
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 20, 25 | Radoff Bradley Louis | sell | 430,000 |
| Aug 20, 25 | PULLY STEVEN J | sell | 239,992 |
| Aug 20, 25 | Eckert Patricia | sell | 25,000 |
| Aug 20, 25 | Eckert Patricia | sell | 28,328 |
| Aug 20, 25 | COUCHMAN JONATHAN | sell | 277,237 |
| Aug 20, 25 | Cannon Kara | sell | 55,400 |
| Aug 20, 25 | Cannon Kara | sell | 45,065 |
| Jan 16, 25 | Radoff Bradley Louis | other | 142,897 |
| Jan 16, 25 | PULLY STEVEN J | other | 142,897 |
| Jan 16, 25 | COUCHMAN JONATHAN | other | 142,897 |
Our ENZB Coverage
We haven't published any research on ENZB yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ENZB Report →